Vivo Capital related stories
All articles and analysis
- Tricida fetches $57.5 mln Series D
South San Francisco, California-based Tricida, Inc, a developer of oral drug therapies, has raised $57.5 million in Series D financing. The investors were Wellington Management Company LLP, Venrock Healthcare Capital Partners, Cormorant Asset Management, OrbiMed, Longitude Capital, Sibling Capital Ventures, Limulus Venture Partners and Vivo Capital.
- Harmony Biosciences racks up $270 mln
Plymouth Meeting, Pennsylvania-based Harmony Biosciences LLC, a biopharmaceutical company, has closed $270 million in funding. The investors included Valor Equity Partners, Fidelity Management & Research Company, HBM Healthcare Investments, Vivo Capital, venBio Partners, Novo Holdings and Nan Fung Life Sciences.
- Homology Medicines racks up $83.5 mln Series B
Bedford, Massachusetts-based Homology Medicines Inc, a genetic medicines company, has raised $83.5 million in Series B financing. Deerfield Management led the round with participation from Fidelity Management and Research Company, HBM Healthcare Investments, Maverick Ventures, Novartis, Rock Springs Capital, Vida Ventures, Vivo Capital, Alexandria Venture Investments, 5AM Ventures, ARCH Venture Partners and Temasek.
- Menlo Therapeutics attracts $50 mln Series C
Menlo Park, California-based Menlo Therapeutics Inc, a pharmaceutical company focused on treating chronic pruritus and chronic cough, has raised $50 million in Series C funding. VenBio led the round with participation from other investors that included Novo Holdings A/S, Rock Springs Capital, Aisling Capital, Bay City Capital, Vivo Capital, Presidio Partners, Remeditex and F-Prime Capital. In addition to the funding, Dr. Aaron Royston of VenBio will join Menlo Therapeutics' board of directors.
- Zai Lab picks up $30 mln Series C
Shanghai-based Zai Lab Limited, a biopharmaceutical company, has secured $30 million in Series C financing. OrbiMed led the round with participation from Vivo Capital, Cormorant and Rock Springs Capital. J.P. Morgan served as placement agent to Zai Lab on the transaction.
- Platelet Biogenesis nabs $10 mln Series A
Biotech startup Platelet Biogenesis has raised $10 million in Series A funding. Qiming led the round with participation from other investors that included Vivo Capital, VI Ventures, Adena Partners and eCoast Angels.
- Verona Pharma debuts IPO
London-based Verona Pharma, a biopharmaceutical company, has priced its IPO of over 5.8 million shares at $13.50 per share. The stock began trading April 27, 2017 on the NASDAQ under the ticker symbol “VRNA.” Jefferies and Stifel are serving as the lead underwriters. Verona Pharma’s backers include Vivo Capital, OrbiMed, New Enterprise Associates, Abingworth, Henderson Global Investors and Aisling Capital.